A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer
Li Deng,1,# Xingfa Ke,4,# Zhiying He,3,# Daoqiu Yang,5 Hai Gong,6 Yingying Zhang,1 Xiaolong Jing,4 Jianzhong Yao,2 Jianming Chen11Department of Pharmaceutics, 2Department of Medicinal Chemistry, School of Pharmacy, 3Department of Cell Biology, Second Military Medical University, Shanghai, People&...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2012
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/3ebfe0cb3ac84ef2aa52ed3bd8290a01 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:3ebfe0cb3ac84ef2aa52ed3bd8290a01 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:3ebfe0cb3ac84ef2aa52ed3bd8290a012021-12-02T07:20:24ZA MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer1176-91141178-2013https://doaj.org/article/3ebfe0cb3ac84ef2aa52ed3bd8290a012012-09-01T00:00:00Zhttp://www.dovepress.com/a-msln-targeted-multifunctional-nanoimmunoliposome-for-mri-and-targeti-a11048https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Li Deng,1,# Xingfa Ke,4,# Zhiying He,3,# Daoqiu Yang,5 Hai Gong,6 Yingying Zhang,1 Xiaolong Jing,4 Jianzhong Yao,2 Jianming Chen11Department of Pharmaceutics, 2Department of Medicinal Chemistry, School of Pharmacy, 3Department of Cell Biology, Second Military Medical University, Shanghai, People's Republic of China; 4Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fujian, People's Republic of China; 5Department of Dermatology, 107th Hospital of PLA, Yantai, People's Republic of China; 6Department of Radiation Oncology, General Hospital of Jinan Military Region, Jinan, People’s Republic of China#These authors contributed equally to this workAbstract: Pancreatic cancer is a highly lethal disease with a 5-year survival rate less than 5% due to the lack of an early diagnosis method and effective therapy. To provide a novel early diagnostic method and targeted therapy for pancreatic cancer, a multifunctional nanoimmunoliposome with high loading of ultrasmall superparamagnetic iron oxides (USPIOs) and doxorubicin (DOX) was prepared by transient binding and reverse-phase evaporation method, and was conjugated with anti-mesothelin monoclonal antibody by post-insertion method to target anti-mesothelin-overexpressed pancreatic cancer cells. The in vitro and in vivo properties of this anti-mesothelin antibody-conjugated PEGlyated liposomal DOX and USPIOs (M-PLDU; and PEGlyated nanoimmunoliposome without antibody conjugation [PLDU]) were evaluated both in human pancreatic cancer cell line Panc-1 cell and in a pancreatic cancer xenograft animal model. Results showed that M-PLDUs were spherical and uniform with a diameter about ~180 nm, with a zeta potential of about −28~−30 mV, and had good efficacy encapsulating DOX and USPIOs. The in vitro study demonstrated that M-PLDUs possessed good magnetic resonance imaging (MRI) capability with a transverse relaxivity (r2) of about 58.5 mM–1 • s–1. Confocal microscopy showed more efficient uptake of M-PLDU in Panc-1 cells by antibody-mediated targeting. Methyl thiazolyl tetrazolium assay results showed significant inhibitory effect of M-PLDU against Panc-1 cells (half-maximal inhibitory concentration, 1.95 µM). The in vivo imaging study showed that the tumor signal intensity (SI) dropped significantly about 4 hours after intravenous injection of M-PLDU. The decrease in tumor SI induced by M-PLDUs (∆ SI = 145.98 ± 20.45) or PLDUs (∆ SI = 75.69 ± 14.53) was much more significant than that by free USPIOs (∆ SI = 42.78 ± 22.12; P < 0.01). The in vivo antitumor study demonstrated that compared with FD (free DOX) and PLDU, M-PLDU possessed higher inhibitory effect on tumor growth and the tissue distribution assay further proved that M-PLDUs could selectively accumulate in the tumor xenograft. These results indicated that M-PLDU not only well retained the inherent MRI capability of USPIOs, but significantly improved the targeting distribution of USPIOs and therapeutic agents in pancreatic tumor tissues. They may serve as a promising theranostic nanomedicine not only for early detection but also for MRI-monitored targeting therapy of human pancreatic cancer.Keywords: theranostic nanomedicine, nanoimmunoliposome, mesothelin, USPIO, doxorubicin, pancreatic cancerDeng LKe XHe ZYang DGong HZhang YJing XYao JChen JDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2012, Iss default, Pp 5053-5065 (2012) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine (General) R5-920 |
| spellingShingle |
Medicine (General) R5-920 Deng L Ke X He Z Yang D Gong H Zhang Y Jing X Yao J Chen J A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer |
| description |
Li Deng,1,# Xingfa Ke,4,# Zhiying He,3,# Daoqiu Yang,5 Hai Gong,6 Yingying Zhang,1 Xiaolong Jing,4 Jianzhong Yao,2 Jianming Chen11Department of Pharmaceutics, 2Department of Medicinal Chemistry, School of Pharmacy, 3Department of Cell Biology, Second Military Medical University, Shanghai, People's Republic of China; 4Department of Pharmacy, Fujian University of Traditional Chinese Medicine, Fujian, People's Republic of China; 5Department of Dermatology, 107th Hospital of PLA, Yantai, People's Republic of China; 6Department of Radiation Oncology, General Hospital of Jinan Military Region, Jinan, People’s Republic of China#These authors contributed equally to this workAbstract: Pancreatic cancer is a highly lethal disease with a 5-year survival rate less than 5% due to the lack of an early diagnosis method and effective therapy. To provide a novel early diagnostic method and targeted therapy for pancreatic cancer, a multifunctional nanoimmunoliposome with high loading of ultrasmall superparamagnetic iron oxides (USPIOs) and doxorubicin (DOX) was prepared by transient binding and reverse-phase evaporation method, and was conjugated with anti-mesothelin monoclonal antibody by post-insertion method to target anti-mesothelin-overexpressed pancreatic cancer cells. The in vitro and in vivo properties of this anti-mesothelin antibody-conjugated PEGlyated liposomal DOX and USPIOs (M-PLDU; and PEGlyated nanoimmunoliposome without antibody conjugation [PLDU]) were evaluated both in human pancreatic cancer cell line Panc-1 cell and in a pancreatic cancer xenograft animal model. Results showed that M-PLDUs were spherical and uniform with a diameter about ~180 nm, with a zeta potential of about −28~−30 mV, and had good efficacy encapsulating DOX and USPIOs. The in vitro study demonstrated that M-PLDUs possessed good magnetic resonance imaging (MRI) capability with a transverse relaxivity (r2) of about 58.5 mM–1 • s–1. Confocal microscopy showed more efficient uptake of M-PLDU in Panc-1 cells by antibody-mediated targeting. Methyl thiazolyl tetrazolium assay results showed significant inhibitory effect of M-PLDU against Panc-1 cells (half-maximal inhibitory concentration, 1.95 µM). The in vivo imaging study showed that the tumor signal intensity (SI) dropped significantly about 4 hours after intravenous injection of M-PLDU. The decrease in tumor SI induced by M-PLDUs (∆ SI = 145.98 ± 20.45) or PLDUs (∆ SI = 75.69 ± 14.53) was much more significant than that by free USPIOs (∆ SI = 42.78 ± 22.12; P < 0.01). The in vivo antitumor study demonstrated that compared with FD (free DOX) and PLDU, M-PLDU possessed higher inhibitory effect on tumor growth and the tissue distribution assay further proved that M-PLDUs could selectively accumulate in the tumor xenograft. These results indicated that M-PLDU not only well retained the inherent MRI capability of USPIOs, but significantly improved the targeting distribution of USPIOs and therapeutic agents in pancreatic tumor tissues. They may serve as a promising theranostic nanomedicine not only for early detection but also for MRI-monitored targeting therapy of human pancreatic cancer.Keywords: theranostic nanomedicine, nanoimmunoliposome, mesothelin, USPIO, doxorubicin, pancreatic cancer |
| format |
article |
| author |
Deng L Ke X He Z Yang D Gong H Zhang Y Jing X Yao J Chen J |
| author_facet |
Deng L Ke X He Z Yang D Gong H Zhang Y Jing X Yao J Chen J |
| author_sort |
Deng L |
| title |
A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer |
| title_short |
A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer |
| title_full |
A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer |
| title_fullStr |
A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer |
| title_full_unstemmed |
A MSLN-targeted multifunctional nanoimmunoliposome for MRI and targeting therapy in pancreatic cancer |
| title_sort |
msln-targeted multifunctional nanoimmunoliposome for mri and targeting therapy in pancreatic cancer |
| publisher |
Dove Medical Press |
| publishDate |
2012 |
| url |
https://doaj.org/article/3ebfe0cb3ac84ef2aa52ed3bd8290a01 |
| work_keys_str_mv |
AT dengl amslntargetedmultifunctionalnanoimmunoliposomeformriandtargetingtherapyinpancreaticcancer AT kex amslntargetedmultifunctionalnanoimmunoliposomeformriandtargetingtherapyinpancreaticcancer AT hez amslntargetedmultifunctionalnanoimmunoliposomeformriandtargetingtherapyinpancreaticcancer AT yangd amslntargetedmultifunctionalnanoimmunoliposomeformriandtargetingtherapyinpancreaticcancer AT gongh amslntargetedmultifunctionalnanoimmunoliposomeformriandtargetingtherapyinpancreaticcancer AT zhangy amslntargetedmultifunctionalnanoimmunoliposomeformriandtargetingtherapyinpancreaticcancer AT jingx amslntargetedmultifunctionalnanoimmunoliposomeformriandtargetingtherapyinpancreaticcancer AT yaoj amslntargetedmultifunctionalnanoimmunoliposomeformriandtargetingtherapyinpancreaticcancer AT chenj amslntargetedmultifunctionalnanoimmunoliposomeformriandtargetingtherapyinpancreaticcancer AT dengl mslntargetedmultifunctionalnanoimmunoliposomeformriandtargetingtherapyinpancreaticcancer AT kex mslntargetedmultifunctionalnanoimmunoliposomeformriandtargetingtherapyinpancreaticcancer AT hez mslntargetedmultifunctionalnanoimmunoliposomeformriandtargetingtherapyinpancreaticcancer AT yangd mslntargetedmultifunctionalnanoimmunoliposomeformriandtargetingtherapyinpancreaticcancer AT gongh mslntargetedmultifunctionalnanoimmunoliposomeformriandtargetingtherapyinpancreaticcancer AT zhangy mslntargetedmultifunctionalnanoimmunoliposomeformriandtargetingtherapyinpancreaticcancer AT jingx mslntargetedmultifunctionalnanoimmunoliposomeformriandtargetingtherapyinpancreaticcancer AT yaoj mslntargetedmultifunctionalnanoimmunoliposomeformriandtargetingtherapyinpancreaticcancer AT chenj mslntargetedmultifunctionalnanoimmunoliposomeformriandtargetingtherapyinpancreaticcancer |
| _version_ |
1718399452390096896 |